Document is current
Any future updates will be listed below
-
Authors
Hulton, Christopher H.
Costa, Emily A. https://orcid.org/0000-0001-7840-2462
Shah, Nisargbhai S.
Quintanal-Villalonga, Alvaro
Heller, Glenn
de Stanchina, Elisa
Rudin, Charles M. https://orcid.org/0000-0001-5204-3465
Poirier, John T. https://orcid.org/0000-0001-9795-5644
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24 CA213274)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 CA129243)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01 CA199215)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24 CA213274)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01 CA129243)
- License Information
-
More Information
Article History
Received: 8 May 2019
Accepted: 31 January 2020
First Online: 9 March 2020
Competing interests
: C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Ascentage, AstraZeneca, BMS, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Loxo and PharmaMar and is on the scientific advisory boards of Elucida, Bridge and Harpoon. All other authors have no competing interests.
